Assessment of tumor radiosensitivity using functional and metabolic nuclear imng in research and clinical practice. A review;Évaluation de la radiosensibilité tumorale par l'imagerie fonctionnelle et métabolique : de la recherche à l'application clinique. Revue de la littérature

Cancer/Radiotherapie

Volumn 10, Issue 3, 2006, Pages 124-133

  Belkacemi Y ^a,b   Tsoutsou, P G ^a,c   Comet, B ^a   Kerrou, K ^d   Lartigau, E ^a,b  

^a CENTRE OSCAR LAMBRET   (France)

^b UNIV LILLE   (France)

^c centre Metaxas   (Greece)

^d HÔPITAL TENON   (France)

Author keywords

Isotopes; Nuclear imaging; PET; Radiosensitivity; Radiotherapy; Tumor response

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; AMINO ACID; ANGIOGENESIS INHIBITOR; ARABINOSIDE; BIOLOGICAL MARKER; CARBON 11; CETUXIMAB; DEOXYURIDINE; FIALURIDINE; FLUORINE 18; FLUOROAZOMYCINARABINOFURANOSIDE; FLUORODEOXYGLUCOSE F 18; FLUOROETANIDAZOLE; GEFITINIB; HORMONE RECEPTOR; IMIDAZOLE DERIVATIVE; IODINE 123; IODINE 124; IODOAZOMYCINEGALACTOSIDE; NUCLEOSIDE; RADIOPHARMACEUTICAL AGENT; RADIOSENSITIZING AGENT; THYMIDINE; TRACER; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT;

ANGIOGENESIS; APOPTOSIS; CANCER CONTROL; CANCER GROWTH; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER THERAPY; CELL PROLIFERATION; CLINICAL PRACTICE; HUMAN; HYPOXIA; IMAGING; MEDICAL RESEARCH; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RADIOSENSITIVITY; SHORT SURVEY; TUMOR CELL; CELL HYPOXIA; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); RADIATION DOSE; REVIEW; SCINTISCANNING; VASCULARIZATION;

CELL HYPOXIA; CELL PROLIFERATION; FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RADIATION TOLERANCE; RADIOPHARMACEUTICALS;

EID: 33646476265     PISSN: 12783218     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canrad.2005.09.022     Document Type: Short Survey

References (81)

1. Abe T., Sakaguchi Y., Ohno S., Ikeda Y., Kitamura K., Maehara Y., et al. Apoptosis and p53 overexpression in human rectal cancer; relationship with response to hyperthermochemoradiotherapy. Anticancer Res. 21 (2001) 2115-2120
2. Adiedj A. Epidermal growth factor receptor tyrosine kinase inhibitors in cancer therapy. Drugs Future 26 (2001) 1087-1092
3. Allal A.S., Dulguerov P., Allaoua M., Haenggeli C.A., El-Ghazi E.A., Lehmann W., et al. Standardized uptake value of 2-[F-18]fluro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J. Clin. Oncol. 20 (2002) 1398-1404
4. Allal A.S., Slosman O., Kebdani T., Allaoua M., Lehmann W., and Dulguerov P. Prediction outcome in head and neck cancer patients using the standardized uptake value of 2-[F-18]fluro-2-deoxy-D-glucose. Int. J. Radiat. Oncol. Biol. Phys. 59 (2004) 1295-1300
5. Anderson H.L., Yap J.T., Miller M.P., Robbins A., Jones T., and Price P.M. Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J. Clin. Oncol. 21 (2003) 2823-2830
6. Barthel H., Wilson H., Collingridge D.R., Brown G., Osman S., Luthra S.K., et al. In vivo evaluation of [18F]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography. Br. J. Cancer 90 (2004) 2232-2242
7. Bartelink H., Begg A., Martin J.C., van Dijk M., van 't Veer L., van der Vaart P., et al. Towards prediction and modulation of treatment response. Radiother. Oncol. 50 (1999) 1-11
8. Baumann M., and Krause M. Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results. Radiother. Oncol. 72 (2004) 257-266
9. Beitler J.J. Mirror, mirror on the wall-which is the greatest predictive assay of them all?. Int. J. Radiat. Oncol. Biol. Phys. 59 (2004) 1272-1273
10. Bentzen L., Keiding S., Horsman M.R., Falborg L., Hansen S.B., and Overgaard J. Feasibility of detecting hypoxia in experimental mouse tumours with 18F-fluorinated tracers and positron emission tomography--a study evaluating [18F]Fluoro-2-deoxy-D-glucose. Acta Oncol. 39 (2000) 629-637
11. 124I] iododeoxyuridine. Cancer Res. 60 (2000) 624-635
12. Boisserie G. Contribution of registered and/or fused image to radiotherapy. Cancer Radiother. 9 (2005) 204-222
13. Bos R., van Der Hoeven J.J., van Der Wall E., van Der Groep P., van Diest P.J., Comans E.F., et al. Biologic correlates of (18) fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J. Clin. Oncol. 20 (2002) 379-387
14. Brady F., Luthra S.K., Brown G.D., Osman S., Aboagye E., Saleem A., et al. Radiolabelled tracers and anticancer drugs for assessment of therapeutic efficacy using PET. Curr. Pharm. Des. 18 (2001) 1863-1892
15. Brahme A. Biologically optimized 3-dimensional in vivo predictive assay-based radiation therapy using positron emission tomography-computerized tomography imaging. Acta Oncol. 42 (2003) 123-136
16. Bristow R.G., and Hill R.P. Molecular and cellular basis of radiotherapy. In: Tannock I.F., and Hill R.P. (Eds). The basis science of oncology. 3rd ed (1987), McGraw-Hill, New York 295-321
17. 2O. J. Nucl. Med. 45 (2004) 1851-1859
18. Brun E., Ohlsson T., Erlandsson K., Kjellen E., Sandell A., Tennvall J., et al. Early prediction of treatment outcome in head and neck cancer with 2-(18)FDG PET. Acta Oncol. 36 (1997) 741-747
19. Chapman J.D., Schneider R.F., Urbain J.L., and Hanks G.E. Single-photon emission computed tomography and positron-emission tomography assays for tissue oxygenation. Sem. Radiat. Oncol. 11 (2001) 47-57
20. Collier T.L., Lecomte R., McCarthy T.J., Meikle S., Ruth T.J., Scopinaro F., et al. Assessment of cancer-associated biomarkers by positron emission tomography: advances and challenges. Dis. Markers 18 (2002) 211-247
21. Corvro R., Antognoni P., and Sanguineti G. Biological predictors of response to radiotherapy in head and neck cancer: recent advances and emerging perspectives. Tumori 87 (2001) 355-363
22. Couturier O., Luxen A., Chatal J.F., Vuillez J.P., Rigo P., and Hustinx R. Fluorinated tracers for imaging cancer with positron emission tomography. Eur. J. Nucl. Med. Mol. Imaging 31 (2004) 1182-1206
23. 11C]tyrosine and 2-[F-18]fluro-2-deoxy-D-glucose. Int. J. Rad. Appl. Instrum. B 18 (1991) 503-511
24. Dehdashti F., Mortimer J.E., Siegel B.A., Griffeth L.K., Bonasera T.J., Fusselman M.J., et al. Positron tomography assessment of estrogen receptors in breast cancer: comparison with FDG PET and in vitro receptor assays. J. Nucl. Med. 36 (1995) 1766-1774
25. Dubois L., Landuyt W., Haustermans K., Dupont P., Bormans G., Vermaelen P., et al. Evaluation of hypoxia in an experimental rat tumour model by [(18)F]Fluoromisonidazole PET and immunohistochemistry. Br. J. Cancer 91 (2004) 1947-1954
26. Dubray B., Breton C., Delic J., Klijanienko J., Maciorowski Z., Vielh P., et al. In vitro radiation-induced apoptosis and early response to low-dose radiotherapy in non-Hodgkin's lymphomas. Radiother. Oncol. 46 (1998) 185-191
27. 18F]EF1. J. Nucl. Med. 41 (2000) 327-336
28. Foo S.S., Abbott D.F., Lawrentschuk N., and Scott A.M. Functional imaging of intratumoral hypoxia. Mol. Imaging Biol. 6 (2004) 291-305
29. Fornace A., Fuchs Z., Weichselbaum R.R., and Milas L. Radiation therapy. In: Mendelsohn J., Howley P.M., Israel M.A., and Liotta L.A. (Eds). The molecular basis of cancer (2001), WB Sanders, Philadelphia 423-454
30. 18F]fluoro-17-α-methyl-5α-dihydrotestos terone: a ligand for receptor mediated imaginf of prostate cancer. Nucl. Med. Biol. 28 (2001) 85-90
31. Gudjonssona O., Bergstrom M., Kristjansson S., Wu F., Nyberg G., Fasth K.J., et al. Analysis of Br-76-BrdU in DNA of brain tumors after a Pet study does not support its use as a proliferative marker. Nucl. Med. Biol. 28 (2001) 59-65
32. Haubner R., Wester H.J., Reuning U., Senekowitsch-Schmidtke R., Diefenbach B., Kessler H., et al. Radiolabeled alpha(v)-beta-3-integrin antagonists: a new class of tracers for tumor targeting. J. Nucl. Med. 40 (1999) 1061-1071
33. 18F-labeled RGD-containing glycopepetide and positron emission tomography. Cancer Res. 61 (2001) 1781-1785
34. Hofstra L., Liem I.H., Dumont E.A., Boersma H.H., van Heerde W.L., Doevendans P.A., et al. Visualisation of cell death in vivo in patients with acute myocardial infarction. Lancet 356 (2000) 209-212
35. Inoue T., Tomiyoshi K., Higuichi T., Ahmed K., Sarwar M., Aoyagi K., et al. Biodistribution studies on L-3-[Fluorine-18]fluoro-alpha-methyl tyrosine:a potential tumor-detecting agent. J. Nucl. Med. 39 (1998) 663-667
36. Joiner M.C., Lambin P., Malaise E.P., Robson T., Arrand J.E., Skov K.A., et al. Hypersensitivity to very low single radiation doses: its relationship to the adaptive response and induced radioresistance. Mutat. Res. 358 (1996) 171-183
37. Koh W.J., Rasey J.S., Evans M.L., Grierson J.R., Lewellen T.K., Graham M.M., et al. Imaging of hypoxia in human tumors with (F-18) fluoromisonidasole. Int. J. Radiat. Oncol. Biol. Phys. 22 (1992) 199-212
38. Krozely P. Epidermal growth factor receptor tyrosine kinase inhibitors: evolving role in the treatment of solid tumors. Clin. J. Oncol. Nurs. 8 (2004) 163-168
39. Lambin P., Malaise E.P., and Joiner M.C. Might intrinsic radioresistance of human tumour cells be induced by radiation?. Int. Radiat. Biol. 69 (1996) 279-290
40. Lara P.C., Perez S., Rey A., and Santana C. Apoptosis in carcinoma of the bladder. Relation with radiation treatment results. Int. J. Radiat. Oncol. Biol. Phys. 43 (1999) 1015-1019
41. Lehtio K., Eskola O., Viljanen T., Oikonen V., Gronroos T., Sillanmaki L., et al. Imaging perfusion and hypoxia with PET to predict radiotherapy response in head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 59 (2004) 971-982
42. Lehtio K., Oikonen V., Gronroos T., Eskola O., Kalliokoski K., Bergman J., et al. Imaging of blood flow and hypoxia in head and neck cancer: initial evaluation with [(15)O]H(2)O and [(18) F]fluoroerythronitroimidazole PET. J. Nucl. Med. 42 (2001) 1643-1652
43. Lewis J.S., and Welch M.J. PET imaging of hypoxia. Q. J. Nucl. Med. 45 (2001) 183-188
44. Lewis J.S., Srinivasan A., Schmidt M.A., and Anderson C.J. In vitro and in vivo evaluation of 64CU-TETA-Tyr-octreotate. A new somatostatine analogue with improved target tissue uptake. Nucl. Med. Biol. 26 (1999) 267-273
45. Li S., Peck-Radosavljevic M., Kienast O., Preitfellner J., Hamilton G., Kurtaran A., et al. Imaging gastrointestinal tumours using vascular endothelial growth factor-165 (VEGF165) receptor scintigraphy. Ann. Oncol. 14 (2003) 1274-1277
46. Lindhomm P., Leskinene S., and Lapela M. Carbone-11-methionine uptake in squamous cell head and neck cancer. J. Nucl. Med. 39 (1998) 1393-1397
47. Mankoff D.A., Dehdashti F., and Shields A.F. Characterizing tumors using metabolic imaging: PET imaging for cellular proliferation and steroid receptors. Neoplasia 2 (2000) 71-88
48. Martin F., and Solary E. Tumor cell resistance to DNA-damaging agents: from apoptosis to neioisis. Curr. Med. Chem. Anti-Cancer Agents 4 (2004) 461-463
49. Mendelsohn M.L. The growth fraction: a new concept applied to tumors. Science 132 (1960) 1496-1503
50. Meyn R.L., Milas L., and Stephens L.C. Apoptosis in tumor biology and therapy. Adv. Exp. Md. Biol. 400 (1997) 657-667
51. Minn H., Lapela M., Klemi P.J., Grenman R., Leskinen S., Lindholm P., et al. Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer. J. Nucl. Med. 38 (1997) 1907-1911
52. Narula J., Acio E.R., Narula N., Samuels L.E., Fyfe B., Wood D., et al. Annexin-V imaging for noninvasive detection of cardiac allograft rejection. Nat. Med. 17 (2001) 1347-1352
53. 99mTc-MIBI and deoxyglucose in mouse breast cancer models. J. Nucl. Med. 41 (2000) 1561-1568
54. Pierotti M.A., and Dragani T.A. Genetics and cancer. Curr. Opin. Oncol. 4 (1992) 127-133
55. 18F]fluorodeoxyglucose positron emission tomography imaging. Clin. Cancer Res. 10 (2004) 2245-2252
56. 99mTc-labeled antihuman epidermal growth factor receptor antibody in patients with tumors of epithelial origin: Part III. Clinical trials safety and diagnostic efficacy. J. Nucl. Med. 40 (1999) 768-775
57. Rasey J.S., Koh W.J., Evans M.L., Peterson L.M., Lewellen T.K., Graham M.M., et al. Quantifying regional hypoxia in human tumors with positron emission tomography of (F-18) fluoromisonidasole: a pretherapy study of 37 patients. Int. J. Radiat. Oncol. Biol. Phys. 36 (1996) 417-428
58. Rege S., Safa A.A., Chaiken L., Hoh C., Juillard G., and Withers H.R. Positron emission tomography: an independant indicator of radiocurability in head an neck carcinoma. Am. J. Clin. Oncol. Cancer Clin. Trials 23 (2000) 164-169
59. Rigo P., Paulus P., Kaschten B.J., Hustinx R., Bury T., Jerusalem G., et al. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur. J. Nucl. Med. 23 (1996) 1641
60. Rodel C., Grabenbauer G.G., Papadopoulos T., Bigalke M., Gunther K., Schick C., et al. Apoptosis as a cellular predictor for histopathologic response to neoadjuvant radiochemotherapy in patients with rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 52 (2002) 294-303
61. Rodel C., Grabenbauer G.G., Rodel F., Birkenhake S., Kuhn R., Martus P., et al. Apoptosis, p53, bcl-2, and Ki-67 in invasive bladder carcinoma: possible predictors for response to radiochemotherapy and successful bladder preservation. Int. J. Radiat. Oncol. Biol. Phys. 46 (2000) 1213-1221
62. Ross G.M. Induction of cell death by radiotherapy. Endocr. Relat. Cancer 6 (1999) 41-44
63. Rowell N.P., McCready V.R., Tait D., Flower M.A., Cronin B., Adams G.E., et al. Technetium-99m HMPAO and SPECT in the assessment of blood flow in human lung tumours. Br. J. Cancer 59 (1989) 135-141
64. Sasaki R., Komaki R., Macapinlac H., Erasmu J., Allen P., Forster K., et al. [18F] fluorodeoxyglucose uptake by positro emission tomography predicts outcome of non-small-cell lung cancer. J. Clin. Oncol. 23 (2005) 1136-1143
65. Sato N., Suzuki M., Kuwata N., Kuroda K., Wada T., Beppu T., et al. Evaluation of the malignacie of glioma using 11C-methionine positron emission tomography and proliferating cell nuclear antigen staining. Neurosurg. Rev. 22 (1999) 210-214
66. Scott N., Hale A., Deakin M., Hand P., Adab F.A., Hall C., et al. A histopathological assessment of the response of rectal adenocarcinoma to combination chemo- radiotherapy: relationship to apoptotic activity, p53 and bcl-2 expression. Eur. J. Surg. Oncol. 24 (1998) 169-173
67. Shields A.F., Larson S.M., Grunbaum Z., and Graham M.M. Short term thymidine uptake in normal and neoplastic tissues: studies for PET. J. Nucl. Med. 25 (1984) 759-764
68. Shulkin B.L., Wieland D.M., Schwaiger M., Thompson N.W., Francis I.R., Haka M.S., et al. PET scanning with hydroxyephedrine: an approach to the localisation of pheochromocytoma. J. Nucl. Med. 33 (1992) 1125-1131
69. Skov K.A. Radioresponsiveness at low doses: hyperradiosensitivity and increased radioresistance in mammalian cells. Mutat. Res. 430 (1999) 241-253
70. Slingerland J.M., and Tannock I.F. Cell proliferation and cell death. In: Tannock I.F., and Hill R.P. (Eds). The basis science of oncology. 3rd ed (1987), McGraw-Hill, New York 134-165
71. Solomon B., McArthur G., Cullinane C., Zalcberg J., and Hicks R. Applications of positron emission tomography in the development of molecular targeted cancer therapeutics. BioDrugs 17 (2003) 339-354
72. 18F]Fluoromisonidazole (18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nucl. Med. Biol. 30 (2003) 317-326
73. Stahl A., Wieder H., Piert M., Wester H.J., Senekowitsch-Schmidtke R., and Schwaiger M. Positron emission tomography as a tool for translational research in oncology. Mol. Imaging Biol. 6 (2004) 214-224
74. Szostak M.J., Kaur P., Amin P., Jacobs S.C., and Kyprianou N. Apoptosis and bcl-2 expression in prostate cancer: significance in clinical outcome after brachytherapy. J. Urol. 165 (2001) 2126-2130
75. Touboul E., Deniaud-Alexandre E., Moureau-Zabotto L., and Lerouge D. The impact of integrating images of positron emission tomography simulation in radiotherapy planing. Cancer Radiother. 8 (2004) S29-S35
76. Urtasun R.C., Parliament M.B., McEwan A.J., Mercer J.R., Mannan R.H., Wiebe L.I., et al. Measurement of hypoxia in human tumors by non-invasive SPECT imaging of iodoazomycin arabinoside. Br. J. Cancer 74 (1996) 209-212
77. Van de Wiele C., Lahorte C., Oyen W., Boerman O., Goethals I., Slegers G., et al. Nuclear medecine imaging to predict response to radiotherapy: a review. Int. J. Radiat. Oncol. Biol. Phys. 55 (2003) 5-15
78. Von Pawel J. Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors. Bull. Cancer 91 (2004) E70-E76
79. Wang G., Dong Z., Xu G., Yang Z., Shou C., Wang N., et al. The effect of antibody against vascular endothelial growth factor on tumor growth and metastasis. J. Cancer Res. Clin. Oncol. 124 (1998) 615-620
80. Wen B., Burgman P., Zanzonico P., O'donoghue J., Cai S., Finn R., et al. A preclinical model for noninvasive imaging of hypoxia-induced gene expression; comparison with an exogenous marker of tumor hypoxia. Eur. J. Nucl. Med. Mol. Imaging 31 (2004) 1530-1538
81. Zanzonico P., O'Donoghue J., Chapman J.D., Schneider R., Cai S., Larson S., et al. Iodine-124-labeled iodo-azomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning. Eur. J. Nucl. Med. Mol. Imaging 31 (2004) 117-128